AutoimmuneICD-10: M32Affects approximately 1.5 million Americans and 5 million worldwide

Lupus

Also known as: Systemic Lupus Erythematosus, SLE

Lupus is a chronic autoimmune disease in which the immune system attacks the body's own tissues, potentially affecting joints, skin, kidneys, brain, heart, and lungs. It is characterized by periods of flares and remission. While once considered fatal, advances in treatment now allow most patients to live full, active lives.

Last updated November 10, 2026

Understanding Lupus

Systemic lupus erythematosus (SLE) is an autoimmune disease in which antibodies form against the body's own cell nuclei and the resulting immune complexes inflame whichever organs they settle in: skin and joints in most people, kidneys in about half, and the blood, lungs, heart or brain in a minority. A CDC-funded analysis of the national lupus registries put the number of Americans living with SLE at about 204,000 (73 per 100,000), though broader estimates that include cutaneous and drug-induced forms reach 1.5 million. Nine in ten patients are women, onset clusters between 15 and 45, and Black, Hispanic, Asian and Native American women are two to four times more likely to be affected than white women and more likely to develop kidney disease. Diagnosis is often delayed by years because the early picture, fatigue, joint pain, mouth ulcers and a rash that comes with the sun, overlaps with a dozen other conditions.

The core defect is a loss of tolerance to nuclear material. Cells that die normally are cleared slowly in lupus, exposing DNA, histones and RNA-protein complexes to an immune system already primed by an overactive type I interferon pathway. B cells make anti-dsDNA and other autoantibodies, these bind their targets to form immune complexes, and the complexes deposit in blood vessels, skin and the kidney's filtering units, consuming complement (which is why C3 and C4 fall during flares) and attracting inflammatory cells. Ultraviolet light drives the process by killing skin cells and releasing more nuclear antigen, which is why 50 to 70 percent of patients are photosensitive and a beach holiday can trigger a systemic flare, not just a rash. The course is relapsing and remitting: flares alternate with quieter periods, and damage accumulates with each flare and with each year on high-dose steroids. Five-year survival now exceeds 95 percent; the long-term threats are kidney failure, infection and premature cardiovascular disease.

Hydroxychloroquine is the backbone of treatment for every patient without a contraindication, and the 2023 EULAR recommendations and the American College of Rheumatology say so explicitly. In the Canadian Hydroxychloroquine Study (1991), patients randomized to stop the drug were 2.5 times more likely to flare over six months than those who continued, and cohort studies since have linked it to fewer clots, less organ damage and roughly a halving of mortality. The dose is capped at 5 mg per kg of actual body weight per day, with a baseline retinal exam and annual screening from year five, because retinal toxicity, rare at that dose, is irreversible. Glucocorticoids control flares, but EULAR now sets a target of 5 mg of prednisone a day or less, and ideally none, because cumulative dose drives damage. Mycophenolate or azathioprine spare steroids; mycophenolate or cyclophosphamide, often with belimumab or voclosporin, treat nephritis. Belimumab (BLISS-52 and BLISS-76, 1,684 patients) and anifrolumab (TULIP-2, 362 patients, 48 versus 32 percent responding) are the first biologics licensed for SLE in half a century.

Natural approaches are adjuncts, and the honest list is short. Vitamin D is the strongest: most people with lupus are deficient, partly because they avoid the sun and partly because the disease and steroids lower levels, and in the Johns Hopkins cohort each 20 ng/mL rise in 25-hydroxyvitamin D was linked to 21 percent lower odds of high disease activity and 15 percent lower odds of significant proteinuria, with small trials showing modest falls in activity scores on supplementation. Omega-3 fish oil has several small trials showing lower activity scores and better blood-vessel function. DHEA, curcumin and N-acetylcysteine each have one or two trials. Then come the things to avoid. Echinacea and other immune-stimulating herbs have been linked to flares in case reports; alfalfa sprouts and tablets contain L-canavanine, which induced a lupus-like illness in monkeys and has reactivated disease in people; spirulina and chlorella carry the same theoretical risk. St John's wort causes photosensitivity and lowers blood levels of cyclosporine and tacrolimus. Garlic supplements are discouraged by patient organizations on weak evidence, and nothing herbal replaces hydroxychloroquine.

The most common mistake is stopping hydroxychloroquine because the disease feels quiet. It takes 3 to 6 months to reach full effect and roughly as long to wear off, so the flare arrives months later and is blamed on something else; in cohort data, non-adherence to the drug is one of the strongest predictors of flares, hospital admission and kidney damage. The second mistake is reading lab results in the wrong frame. In lupus the ESR typically rises with disease activity while the CRP stays low or normal, because interferon suppresses CRP production; a high CRP in someone with lupus points first to infection, serositis or arthritis rather than a flare, and infection is more dangerous on immunosuppressants. Ask what your anti-dsDNA, complement, creatinine, eGFR, albumin, platelets and urine protein are doing over time rather than reacting to any single number, and keep copies of your own results so a new clinician can see the trend.

At a Glance

Common symptoms
Butterfly-shaped facial rash (malar rash), Joint pain, stiffness, and swelling, Extreme fatigue
Main treatments
Hydroxychloroquine — recommended for all lupus patients, NSAIDs for mild joint pain, Corticosteroids for flare management
Category
Autoimmune · Affects approximately 1.5 million Americans and 5 million worldwide
See a doctor if
Unexplained rash, persistent joint pain, or fever

Symptoms

Butterfly-shaped facial rash (malar rash)
Joint pain, stiffness, and swelling
Extreme fatigue
Skin lesions worsening with sun exposure
Fever with no other cause
Raynaud's phenomenon
Hair loss
Mouth or nose ulcers
Chest pain from pleurisy or pericarditis
Kidney problems (lupus nephritis)

Causes

  • Autoimmune dysfunction attacking healthy tissue
  • Genetic predisposition involving multiple susceptibility genes
  • Environmental triggers (UV light, infections, certain medications)
  • Hormonal factors (estrogen may play a role)

Risk Factors

  • Female sex (9 out of 10 patients are women)
  • Age 15–45 (childbearing years)
  • African American, Hispanic, Asian, and Native American descent
  • Family history of lupus or autoimmune diseases
  • Certain medications can trigger drug-induced lupus

Diagnosis

  • ANA test (positive in >95% of SLE patients)
  • Anti-dsDNA and anti-Smith antibody tests (specific to SLE)
  • CBC, complement levels (C3, C4), and urinalysis
  • Clinical criteria combining symptoms, labs, and organ involvement
  • Kidney biopsy if lupus nephritis is suspected

Treatment

  • Hydroxychloroquine — recommended for all lupus patients
  • NSAIDs for mild joint pain
  • Corticosteroids for flare management
  • Immunosuppressants (mycophenolate, azathioprine, cyclophosphamide)
  • Belimumab (biologic targeting B-lymphocyte stimulator)
  • Anifrolumab (anti-interferon biologic) for moderate-to-severe SLE

Natural remedies for lupus: what the evidence says

Ranked by the strength of human evidence for lupus specifically. These sit alongside medical care, not in place of it.

  1. Vitamin D

    Moderate evidence

    In the Johns Hopkins Lupus Cohort (1,006 patients), each 20 ng/mL higher 25-hydroxyvitamin D level was associated with 21 percent lower odds of high disease activity and 15 percent lower odds of clinically important proteinuria. In a 12-month randomized trial of 267 patients, 2,000 IU daily lowered disease activity scores, anti-dsDNA and inflammatory markers compared with placebo, and a 24-week trial of 50,000 IU weekly in 40 adolescents reduced activity and fatigue. Other trials found no difference, so the benefit is probably confined to people who are deficient, which is most patients.

    Studied dose
    1,000 to 2,000 IU vitamin D3 daily, or 50,000 IU weekly for 8 to 12 weeks if a 25-hydroxyvitamin D level is below 20 ng/mL, then rechecked.
    Cautions
    Check a 25-hydroxyvitamin D level before and 3 months after starting; aim for 30 to 50 ng/mL, not higher. High doses can raise blood calcium, which matters with kidney involvement or thiazide diuretics.
  2. Omega-3

    Moderate evidence

    In a 24-week double-blind trial of 60 patients, 3 g daily of EPA plus DHA improved disease activity on two validated scores and improved endothelial function and oxidative stress markers compared with placebo. A 2004 trial in 52 patients found similar activity improvements, and a 6-month trial of 50 patients reported less fatigue and better physician global assessment. The trials are small and short, so the effect is modest and the evidence Moderate at best.

    Studied dose
    2 to 3 g combined EPA and DHA daily from fish oil, taken with food.
    Cautions
    Adds to bleeding risk with warfarin, apixaban, rivaroxaban or aspirin at doses above 3 g; can raise LDL cholesterol slightly. Choose a purified product to avoid mercury and oxidized oil.
  3. DHEA

    Preliminary evidence

    Prasterone (DHEA) 200 mg daily has been tested in seven randomized trials totaling 842 patients with mild to moderate SLE. A Cochrane review found no clinically important effect on disease activity but a modest, significant improvement in health-related quality of life, and two trials showed more patients could lower prednisone to 7.5 mg or less. Bone density also improved in women on steroids.

    Studied dose
    200 mg prasterone daily in trials; over-the-counter DHEA products are unregulated and vary in content.
    Cautions
    Acne, oily skin and hirsutism in a third of users; may lower HDL cholesterol and raise estrogen and testosterone, so avoid with hormone-sensitive cancers or in pregnancy. Treat it as a hormone and use only with your rheumatologist's agreement.
  4. Curcumin

    Preliminary evidence

    In a 3-month randomized trial of 24 patients with relapsing or refractory lupus nephritis, 500 mg of turmeric (22 mg curcumin) three times daily lowered proteinuria, hematuria and systolic blood pressure compared with placebo. That is one tiny trial at a very low curcumin dose, and no trial has tested curcumin for systemic activity or skin disease.

    Studied dose
    500 mg turmeric powder three times daily with meals was the studied dose; 500 mg to 1 g of a bioavailable curcumin extract daily is the usual supplement range.
    Cautions
    Curcumin inhibits platelet function and interacts with warfarin, can raise tacrolimus levels, and binds iron, which worsens iron deficiency. Stop two weeks before surgery or a kidney biopsy.
  5. NAC

    Preliminary evidence

    In a 3-month double-blind trial of 36 patients, 2.4 g or 4.8 g of N-acetylcysteine daily lowered SLEDAI and BILAG disease activity scores and fatigue compared with placebo, with changes in T-cell signaling that fit lupus biology. A larger phase II trial has followed, but the published evidence is still one small trial.

    Studied dose
    2.4 g daily in divided doses (the 4.8 g dose caused nausea in the trial).
    Cautions
    Nausea and reflux at higher doses; may increase bleeding with anticoagulants. No interaction with hydroxychloroquine is known.

What matters day to day

  • Apply a broad-spectrum SPF 50 sunscreen every morning, reapply every two hours outdoors, and wear UPF clothing and a hat: UVA passes through window glass and cloud, and in photoprovocation studies a broad-spectrum sunscreen prevented UV-triggered lesions in patients who all developed them unprotected.
  • Stop smoking: smokers with lupus have roughly double the skin disease activity and respond less well to hydroxychloroquine, and smoking adds to a cardiovascular risk that is already five to ten times higher than average.
  • Keep vaccinations current (inactivated flu, pneumococcal, recombinant shingles, HPV and COVID): infection is the leading cause of death in the first years after diagnosis, and live vaccines must be avoided on most immunosuppressants, so plan them with your rheumatologist.
  • Exercise three times a week: supervised aerobic programs reduced fatigue and improved fitness in randomized trials without increasing disease activity, and fatigue is the symptom patients rate as most disabling.
  • Treat heart risk as part of lupus care: in the Pittsburgh cohort, women with lupus aged 35 to 44 had a 50-fold higher heart attack rate than women without it, so blood pressure, LDL cholesterol and A1c should be checked yearly and treated to target.
  • Plan pregnancy rather than discovering it: disease should be quiet for six months, hydroxychloroquine is continued (it lowers flare risk and congenital heart block in anti-Ro-positive mothers), mycophenolate and methotrexate must be stopped well before conception, and low-dose aspirin from 12 weeks reduces preeclampsia risk.

Prevention

  • No known way to prevent lupus
  • Avoid triggers: excessive sun exposure, smoking, certain medications
  • Use sunscreen (SPF 30+) and protective clothing daily
  • Get adequate rest and manage stress

When to See a Doctor

  • Unexplained rash, persistent joint pain, or fever
  • Extreme fatigue that does not improve with rest
  • Swelling or decreased urine output (possible kidney involvement)
  • Lupus symptoms are flaring despite treatment

Frequently Asked Questions

References

  1. Fanouriakis A, Kostopoulou M, Andersen J, et al.. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Annals of the Rheumatic Diseases (2024)
  2. Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. New England Journal of Medicine (1991)
  3. Izmirly PM, Parton H, Wang L, et al.. Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries. Arthritis & Rheumatology (2021)
  4. Petri M, Bello KJ, Fang H, Magder LS. Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis & Rheumatism (2013)
  5. Abou-Raya A, Abou-Raya S, Helmii M. The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized placebo-controlled trial. Journal of Rheumatology (2013)
  6. Wright SA, O'Prey FM, McHenry MT, et al.. A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Annals of the Rheumatic Diseases (2008)
  7. Crosbie D, Black C, McIntyre L, et al.. Dehydroepiandrosterone for systemic lupus erythematosus. Cochrane Database of Systematic Reviews (2007)
  8. Marmor MF, Kellner U, Lai TY, et al.. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology (2016)
  9. Morand EF, Furie R, Tanaka Y, et al.. Trial of anifrolumab in active systemic lupus erythematosus. New England Journal of Medicine (2020)
  10. MedlinePlus, National Library of Medicine. Lupus (2024)View source

Related Conditions

Related from the Supplement Library

These supplements have been studied in relation to Lupus. Always consult your healthcare provider before starting any supplement, especially if you take medications.

Have questions about Lupus?

Ask Mother Nature AI for personalized, evidence-based guidance.

Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.